Journal article
BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial
Abstract
INTRODUCTION: BAY 81-8973, a full-length recombinant factor VIII for hemophilia A treatment, has been extensively evaluated in previously treated patients in the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical trials.
AIM: To assess BAY 81-8973 efficacy and safety when used for bleed prophylaxis and treatment in previously untreated/minimally treated patients (PUPs/MTPs).
Authors
Ljung R; Chan AKC; Glosli H; Afonja O; Becker B; Tseneklidou-Stoeter D; Mancuso ME; Saulyte-Trakymiene S; Kenet G
Journal
Thrombosis and Haemostasis, Vol. 123, No. 01, pp. 027–039
Publisher
Thieme
Publication Date
January 2023
DOI
10.1055/s-0042-1757876
ISSN
0340-6245